Mourad Tiab
- Hematology top 5%
- Multiple Myeloma Research and Treatments 28
- Autoimmune and Inflammatory Disorders Research 5
-
- Cancer Treatment and Pharmacology 12
- Peptidase Inhibition and Analysis 4
-
- Protein Degradation and Inhibitors 10
-
- Chronic Lymphocytic Leukemia Research 6
- Myeloproliferative Neoplasms: Diagnosis and Treatment 3
-
- Peripheral Neuropathies and Disorders 3
- Co-authors
- Philippe MoreauFrançoise MéchinaudThierry FaçonHervé Avet‐LoiseauJean‐Luc HarousseauXavier LeleuMichel AttalLaurent Garderet
- Cited by
- HematologyOncologyMolecular Biology
- Partner nations
- FranceCanadaUnited States
In The Last Decade
Mourad Tiab
40 papers receiving 399 citations
Peers
Comparison fields: 5 of 45
- Hematology 347
- Oncology 175
- Molecular Biology 270
- Genetics 41
- Infectious Diseases 49
Countries citing papers authored by Mourad Tiab
This map shows the geographic impact of Mourad Tiab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mourad Tiab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mourad Tiab more than expected).
Fields of papers citing papers by Mourad Tiab
This network shows the impact of papers produced by Mourad Tiab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mourad Tiab. The network helps show where Mourad Tiab may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mourad Tiab, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 28 | |
| 2 | 2024 | 1 | |
| 3 | 2022 | 8 | |
| 4 | 2020 | 5 | |
| 5 | 2019 | 6 | |
| 6 | 2019 | 3 | |
| 7 | 2019 | 4 | |
| 8 | 2012 | 83 | |
| 9 | 2012 | 2 | |
| 10 | 2012 | 14 | |
| 11 | 2012 | 5 | |
| 12 | 2011 | 33 | |
| 13 | Bortezomib Plus Dexamethasone Versus Reduced-dose Bortezomib Plus Thalidomide-dexamethasone As Induction Prior To Autologous Transplantation in Newly Diagnosed Myeloma | 2010 | 4 |
| 14 | 2009 | 0 | |
| 15 | 2009 | 3 | |
| 16 | 2003 | 5 | |
| 17 | 2000 | 35 | |
| 18 | [Hemophagocytic syndromes. A series of 23 cases]. | 1996 | 19 |
| 19 | 1996 | 5 | |
| 20 | [Empirical treatment of febrile episodes in granulocytopenic patients with a combination of piperacillin and ofloxacin. Preliminary study]. | 1990 | 1 |
About Mourad Tiab
Mourad Tiab is a scholar working on Hematology, Genetics and Oncology, having authored 42 papers that have together received 407 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (28 papers), Cancer Treatment and Pharmacology (12 papers), Protein Degradation and Inhibitors (10 papers), Chronic Lymphocytic Leukemia Research (6 papers), Autoimmune and Inflammatory Disorders Research (5 papers), Peptidase Inhibition and Analysis (4 papers), Peripheral Neuropathies and Disorders (3 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). The work is most often cited by research in Hematology (347 citations), Oncology (175 citations) and Molecular Biology (270 citations). Mourad Tiab has collaborated with scholars based in France, Canada and United States. Frequent co-authors include Philippe Moreau, Françoise Méchinaud, Thierry Façon, Hervé Avet‐Loiseau, Jean‐Luc Harousseau, Xavier Leleu, Michel Attal, Laurent Garderet, Denis Caillot and Gérald Marit. Their work appears in journals such as Journal of Clinical Oncology, Blood, HemaSphere, Leukemia and European Journal of Internal Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.